Prostate derived factor in human prostate cancer cells: Gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth

Journal of Cellular Physiology

Volumn 208, Issue 3, 2006, Pages 566-574

  Lambert, James R ^a,d   Kelly, Julie A ^a   Shim, Minsub ^b   Huffer, William E ^a   Nordeen, Steven K ^a   Baek, Seung Joon ^c   Eling, Thomas E ^b   Lucia, M Scott ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c UNIVERSITY OF TENNESSEE   (United States)

^d Mail Stop 8104 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; PROTEIN P53; SECOSTEROID; STEROID HORMONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENIC ACTIVITY; CELL CLONING; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DNA FINGERPRINTING; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE INTERACTION; GENETIC ANALYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KNOCKOUT GENE; MALE; NONHUMAN; NULL ALLELE; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DERIVED FACTOR GENE; PROTEIN INDUCTION; RAT; REGULATORY MECHANISM; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; XENOGRAFT;

ANIMALS; BONE MORPHOGENETIC PROTEINS; CALCITRIOL; CELL DIVISION; CELL LINE, TUMOR; DNA PRIMERS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RATS; RATS, NUDE; RNA, NEOPLASM; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33746553766     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20692     Document Type: Article

References (46)

1. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. 2001. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59:901-908.
2. Baek SJ, Wilson LC, Eling TE. 2002. Resveratrol enhances the expression of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 23:425-434.
3. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL. 2004. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303:848-851.
4. Blazsek I, Farabos C, Musset M, Goldschmidt E, Comisso M, Benavides M, Wang ZY, Labat ML, Mathe G, Misset JL. 1991. Retinoic acid in mono- or combined differentiation therapy of myelodysplasia and acute promyelocytic leukemia. Biomed Pharmacother 45:169-177.
5. Bootcov MR, Bauskin AE, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN. 1997. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA 94:11514-11519.
6. Brown DA, Breit SN, Buring J, Fairlie WD, Bauskin AE, Liu T, Ridker PM. 2002. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: A nested case-control study. Lancet 359:2159-2163.
7. Cardillo MR, Petrangeli E, Perracchio L, Salvatori L, Ravenna L, Di Silverio F. 2000. Transforming growth factor-beta expression in prostate neoplasia. Anal Quant Cytol Histol 22:1-10.
8. Cheskis B, Freedman LP. 1994. Ligand modulates the conversion of DNA-bound vitamin D3 receptor (VDR) homodimers into VDR-retinoid X receptor heterodimers. Mol Cell Biol 14:3329-3338.
9. Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N. 1993. Vitamin D and prostate cancer: A prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2:467-472.
10. Danielpour D. 1996. Induction of transforming growth factor-beta autocrine activity by all-trans-retinoic acid and 1 alpha,25-dihydroxyvitamin D3 in NRP-152 rat prostatic epithelial cells. J Cell Physiol 166:231-239.
11. DeLuca HF, Ostrem V. 1986. The relationship between the vitamin D system and cancer. Adv Exp Med Biol 206:413-429.
12. 3 modulated gene expression patterns in human primary normal and cancer prostate cells. J Cell Biochem 93:271-285.
13. Hanchette CL, Schwartz GG. 1992. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70:2861-2869.
14. Hromas R, Hufford M, Sutton J, Xu D, Li Y, Lu L. 1997. PLAB, a novel placental bone morphogenetic protein. Biochim Biophys Acta 1354:40-44.
15. Hsiao EC, Koniaris LG, Zimmers-Koniaris T, Sebald SM, Huynh TV, Lee SJ. 2000. Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol 20:3742-3751.
16. Ilio KY, Sensibar JA, Lee C. 1995. Effect of TGF-beta 1, TGF-alpha, and EGF on cell proliferation and cell death in rat ventral prostatic epithelial cells in culture. J Androl 16:482-490.
17. Karan D, Chen SJ, Johansson SL, Singh AP, Paralkar VM, Lin MF, Batra SK. 2003. Dysregulated expression of MIC-1/PDF in human prostate tumor cells. Biochem Biophys Res Commun 305:598-604.
18. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Lang S, Kato M, Oefelein MG, Miyazono K, Nemeth JA, Kozlowski JM, Lee C. 1996. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 2:1255-1261.
19. Lambert JR, Nordeen SK. 2003. CBP recruitment and histone acetylation in differential gene induction by glucocorticoids and progestins. Mol Endocrinol 17:1085-1094.
20. Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Choi I, Lee JH. 2003. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 63:4648-4655.
21. Li PX, Wong J, Ayed A, Ngo D, Brade AM, Arrowsmith C, Austin RC, Klamut HJ. 2000. Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 275:20127-20135.
22. Liu T, Bauskin AE, Zaunders J, Brown DA, Pankhurst S, Russell PJ, Breit SN. 2003. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 63:5034-5040.
23. Lucia MS, Sporn MB, Roberts AB, Stewart LV, Danielpour D. 1998. The role of transforming growth factor-beta1, -beta2, and -beta3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells. J Cell Physiol 175:184-192.
24. Martikainen P, Kyprianou N, Isaacs JT. 1990. Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology 127:2963-2968.
25. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P. 1992. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res 52:515-520.
26. Moffatt KA, Johannes WU, Miller GJ. 1999. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 5:695-703.
27. Motomura S, Kanamori H, Maruta A, Kodama F, Ohkubo T. 1991. The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am J Hematol 38:67-68.
28. Nakamura T, Scorilas A, Stephan C, Yousef GM, Kristiansen G, Jung K, Diamandis EP. 2003. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer 88:1101-1104.
29. Nazarova N, Qiao S, Golovko O, Lou Y-R, Tuohimaa P. 2004. Calcitriol-induced prostate-derived factor: Autocrine control of prostate cancer cell growth. Int J Cancer 112:951-958.
30. Newman D, Sakaue M, Koo JS, Kim KS, Baek SJ, Eling T, Jetten AM. 2003. Differential regulation of nonsteroidal anti-inflammatory drug-activated gene in normal human tracheobronchial epithelial and lung carcinoma cells by retinoids. Mol Pharmacol 63:557-564.
31. Paralkar VM, Vail AL, Grasser WA, Brown TA, Xu H, Vukicevic S, Ke HZ, Qi H, Owen TA, Thompson DD. 1998. Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem 273:13760-13767.
32. 3 receptor. Nucleic Acids Res 34:543-554.
33. Schwartz GG, Hulka BS. 1990. Is vitamin D deficiency a risk factor for prostate cancer? Anticancer Res 10:1307-1311.
34. Shabahang M, Buras RR, Davoodi F, Schumaker LM, Nauta RJ, Uskokovic MR, Brenner RV, Evans SR. 1994. Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihydroxyvitamin D3. Cancer Res 54:4057-4064.
35. Stewart LV, Weigel NL. 2004. Vitamin D and prostate cancer. Exp Biol Med 229:277-284.
36. Strelau J, Sullivan A, Bottner M, Lingor P, Falkenstein E, Suter-Crazzolara C, Galter D, Jaszai J, Krieglstein K, Unsicker K. 2000. Growth/differentiation factor-15/macrophage inhibitory cytokine-1 is a novel trophic factor for midbrain dopaminergic neurons in vivo. J Neurosci 20:8597-8603.
37. Sutkowski DM, Fong CJ, Sensibar JA, Rademaker AW, Sherwood ER, Kozlowski JM, Lee C. 1992. Interaction of epidermal growth factor and transforming growth factor beta in human prostatic epithelial cells in culture. Prostate 21:133-143.
38. Tan M, Wang Y, Guan K, Sun Y. 2000. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci USA 97:109-114.
39. Thomas R, True LD, Lange PH, Vessella RL. 2001. Placental bone morphogenetic protein (PLAB) gene expression in normal, pre-malignant and malignant human prostate: Relation to tumor development and progression. Int J Cancer 93:47-52.
40. Toell A, Gonzalez MM, Ruf D, Steinmeyer A, Ishizuka S, Carlberg C. 2001. Different molecular mechanisms of vitamin D(3) receptor antagonists. Mol Pharmacol 59:1478-1485.
41. Tong S, Marjono B, Brown DA, Mulvey S, Breit SN, Manuelpillai U, Wallace EM. 2004. Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage. Lancet 363:129-130.
42. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. 2003. Molecular characterization of human prostate carcinoma cell lines. Prostate 57:205-225.
43. Walczak J, Wood H, Wilding G, Williams T, Jr., Bishop CW, Carducci M. 2001. Prostate cancer prevention strategies using antiproliferative or differentiating agents. Urology 57:81-85.
44. Walters MR. 1992. Newly identified actions of the vitamin D endocrine system. Endocr Rev 13:719-764.
45. Wilding G. 1991. Response of prostate cancer cells to peptide growth factors: Transforming growth factor-beta. Cancer Surv 11:147-163.
46. Yang H, Filipovic Z, Brown D, Breit SN, Vassilev LT. 2003. Macrophage inhibitory cytokine-1: A novel biomarker for p53 pathway activation. Mol Cancer Ther 2:1023-1029.